Complement-fixing properties of antinuclear antibodies distinguish drug-induced lupus from systemic lupus erythematosus

Lupus

Volumn 13, Issue 4, 2004, Pages 249-256

  Rubin, Robert L ^a   Teodorescu, M ^b,c   Beutner, E H ^d   Plunkett, R W ^d  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c Thera Test laboratories Inc   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

Complement fixing antinuclear antibodies; Drug induced lupus; Systemic lupus erythematosus

Indexed keywords

ACEBUTOLOL; ANTIGEN; ANTINUCLEAR ANTIBODY; COMPLEMENT FIXING ANTIBODY; DRUG; HYDRALAZINE; METHYLDOPA; PROCAINAMIDE; SMOOTH MUSCLE ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL ARTICLE; COMPLEMENT FIXATION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPATHOLOGY; INFLAMMATION; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 2442567698     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu1007oa     Document Type: Article

References (42)

1. Hess EV, Mongey A-B. Drug-related lupus: The same as or different from idiopathic disease? In: Lahita RG (ed) Systemic Lupus Erythematosus. Churchill Livingstone: New York, 1993, 893-904.
2. Burlingame RW, Rubin RL. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 1991; 88: 680-90.
3. Tan EM. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44: 93-151.
4. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25(11): 1271-77.
5. Fries JF. Methodology of validation of criteria for SLE. Scand J Rheumatol 1987; 65(suppl): 25-30.
6. Schur PH. Complement and systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois' Lupus Erythematosus. Williams and Wilkens: Baltimore, 1997, 245-62.
7. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279: 1052-54.
8. Ignat GP, Rat AC, Sychra JJ, Vo J, Varga J, Teodorescu M. Information on diagnosis and management of systemic lupus erythematosus derived from the routine measurement of 8 nuclear autoantibodies. J Rheumatol 2003; 30: 1761-69.
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
10. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-18.
11. Wluka AE, Liang MH, Partridge AJ et al. Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation. Arthritis Rheum 1997; 40: 57-61.
12. Rubin RL. Drug-induced lupus. In: Wallace DJ, Hahn BH (eds) Dubois' Lupus Erythematosus. Lippincott Williams & Wilkins: Philadelphia, 2002, 885-916.
13. Totoritis MC, Tan EM, McNally EM, Rubin RL. Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N Engl J Med 1988; 318: 1431-36.
14. Rubin RL, Burlingame RW, Arnott JE, Totoritis MC, McNally EM, Johnson AD. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus. J Immunol 1995; 154: 2483-93.
15. Beutner EH, Pelton S, Hashimoto T et al. A nonfatal case and 2 fatal cases of paraneoplastic pemphigus: can a complement indirect immunofluorescent test help to identify fatal "group A" paraneoplastic pemphigus cases? J Am Acad Dermatol 2002; 47: 841-51.
16. Beutner EH, Nisengard RJ, Kumar V. Defined immunofluorescence: basic concepts and their application to clinical immunodermatology. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the Skin. John Wiley and Sons: New York, 1979, 29-75.
17. Nakabayashi T, Kumagai T, Yamauchi K et al. Evaluation of the automatic fluorescent image analyzer, Image Titer, for quantitative analysis of antinuclear antibodies. Am J Clin Pathol 2001; 115: 424-29.
18. Flessland KA, Landicho HR, Borden KK, Prince HE. Performance characteristics of the PolyTiter Immunofluorescent Titration system for determination of antinuclear antibody endpoint dilution. Clin Diagn Lab Immunol 2002; 9: 329-32.
19. Morgan BP. Complement. In: van Oss CJ, Van Regemortel MHV (eds) Immunochemistry. Marcel Dekker, Inc: New York, 1994, 903-24.
20. Robbins WC, Holman HR, Deicher H, Kunkel HG. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc Soc Exp Biol Med 1957; 96: 575.
21. Puritz EM, Yount WJ, Newell M, Utsinger PD. Immunoglobulin classes and IgG subclasses of human antinuclear antibodies. A correlation of complement fixation and the nephritis of systemic lupus erythematosus. Clin Immunol Immunopathol 1973; 2: 98-113.
22. Klajman A, Farkas R, Ben-Efraim S. Complement-fixing activity of antinuclear antibodies induced by procainamide treatment. Isr J Med Sci 1973; 9: 627-30.
23. Rothfield NF, Stollar BD. The relation of immunoglobulin class, pattern of antinuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 1967; 46: 1785-94.
24. Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968; 278: 533-38.
25. Fritzler M, Ryan P, Kinsella TD. Clinical features of systemic lupus erythematosus patients with antihistone antibodies. J Rheumatol 1982; 9(1): 46-51.
26. Diaz Gill GA, Beutner EH, Eisenberg RB. Quantitative studies of immunofluorescent staining. VI. Defined complement immunofluorescent staining for antinuclear antibodies in systemic lupus and other collagen diseases. Int Arch Allergy Appl Immunol 1973; 45: 868-79.
27. Beutner EH, Binder WL, Fang YV, Plunkett RW, Rubin RL. Antinuclear antibodies (ANA) and complement fixing ANA in systemic connective tissue diseases. Immunol Invest 1998; 27: 97-104.
28. Rubin RL, Tang F-L, Chan EKL, Pollard KM, Tsay G, Tan EM. IgG subclasses of autoantibodies in systemic lupus erythematosus, Sjogren's syndrome, and drug-induced autoimmunity. J Immunol 1986; 137: 2528-34.
29. Zouali M, Jefferis R, Eyquem A. IgG subclass distribution of autoantibodies to DNA and to nuclear ribonucleoproteins in autoimmune diseases. Immunology 1984; 51: 595-600.
30. Eisenberg RA, Dyer K, Craven SY, Fuller CR, Yount WJ. Subclass restriction and polyclonality of the systemic lupus erythematosus marker antibody anti-Sm. J Clin Invest 1985; 75: 1270-77.
31. Schur PH, Monroe M, Rothfield N. The gamma-G subclass of antinuclear and antinucleic acid antibodies. Arthritis Rheum 1972; 15: 174-82.
32. Kanayama Y, Peebles C, Tan EM, Curd JG. Complement activating abilities of defined antinuclear antibodies. Arthritis Rheum 1986; 29: 748-54.
33. Rubin RL, Reimer G, McNally EM, Nusinow SR, Searles RP, Tan EM. Procainamide elicits a selective autoantibody immune response. Clin Exp Immunol 1986; 63: 58-67.
34. Peng SL, Craft JE. Spliceosomal snRNPs autoantibodies. In: Peter JB, Shoenfeld Y (eds) Autoantibodies. Elsevier: Amsterdam, 1996, 774-82.
35. Arnett FC, Hamilton RG, Roebber MG, Harley JB, Reichlin M. Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheumatol 1988; 15: 1773-76.
36. Abuaf N, Johanet C, Chretien P, Absalon BI, Homberg JC, Buri JF. Detection of autoantibodies to Sm antigen in systemic lupus erythematosus by immunodiffusion, ELISA and immunoblotting: variability of incidence related to assays and ethnic origin of patients. Eur J Clin Invest 1990; 20: 354-59.
37. Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981; 60: 208-17.
38. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989; 46: 183-219.
39. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275-90.
40. Sekine H, Reilly CM, Molano ID et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001; 166: 6444-51.
41. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996; 93: 8563-68.
42. Matsumoto K, Watanabe N, Akikusa B et al. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Arthritis Rheum 2003; 48: 486-94.